CuraScientific (CuraScientific) EBIT per Share : $0.00 (TTM As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is CuraScientific EBIT per Share?

CuraScientific's EBIT per Share for the three months ended in Sep. 2023 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CuraScientific's EBIT per Share or its related term are showing as below:

CSTF's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

CuraScientific's EBIT for the three months ended in Sep. 2023 was $-5.56 Mil.

CuraScientific EBIT per Share Historical Data

The historical data trend for CuraScientific's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific EBIT per Share Chart

CuraScientific Annual Data

Trend

Dec20

Dec21

Dec22

EBIT per Share

-76.20

-15.50

-0.86

CuraScientific Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial							0.09	-0.25	-0.03	0.29	-0.01

CuraScientific EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CuraScientific's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.049	/	4.726
=	-0.86

CuraScientific's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.561	/	756.677
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

CuraScientific (OTCPK:CSTF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CuraScientific EBIT per Share Related Terms

Thank you for viewing the detailed overview of CuraScientific's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CuraScientific (CuraScientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236

Website

https://www.curascientificcorp.com

CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.

Executives

Paul Quentin Goyette	director	2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed	director, officer: Chief Executive Officer	333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen	director	C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette	director	13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez	director, officer: Chief Executive Officer	15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson	director, officer: Chief Operating Officer	19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Boon Industries Moves Forward With New Technology & Intellectual Property

By Marketwired Marketwired • 05-19-2020

BOON Industries Announces Initial Purchase Order With Major Beverage Company of 500,000 Units

By Marketwired Marketwired • 05-21-2020

BOON to Announce Major Contract Start Date for DIOX+ $52M Revenue Stream

By Marketwired Marketwired • 02-03-2021

BOON Industries Debuts DiOx+ With $2M in Projected Revenue for Next 12 Months

By Marketwired Marketwired • 05-27-2020

Introducing Leaf of Faith

By Marketwired Marketwired • 03-26-2019